Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule inhibitor of heat shock protein 90-alpha (HSP90α), a molecular chaperone involved in the folding and stabilization of various client proteins critical for cancer cell survival. It belongs to the class of phenylpyridines and quinazolines. The drug is experimental and has not been approved for any indication. Its primary mechanism is inhibition of HSP90α activity, which may disrupt multiple oncogenic signaling pathways dependent on this chaperone[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime.